bremelanotide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-29. Numbers and descriptions here follow the published literature rather than marketing material.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-MSH |
| Molecular mass | Approximately 1025 Da | Peptide-scale molecule |
| Route | Subcutaneous injection | Intranasal form used in early research |
| Common synonyms | PT-141; bremelanotide acetate | Research code and salt form |
| Typical storage | 2-8 °C, protected from light | Unopened vial condition |
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
From a pharmacokinetic standpoint, the peptide is usually delivered by injection because oral bioavailability is very low; proteases in the digestive tract degrade it rapidly. After subcutaneous administration, plasma concentrations reach a peak within roughly one hour. Its elimination half-life is relatively short, with most reports placing it in the range of a few hours. Nasal formulations have also been examined, though absorption varies widely between individuals. Metabolism proceeds mainly through peptidase cleavage, and the resulting products are excreted by the kidneys.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
In the first reaction the bidentate ligand ethylene diamine forms a chelate complex with the copper ion. Chelation results in the formation of a five-membered ring. In the second reaction the bidentate ligand is replaced by two monodentate methylamine ligands of approximately the same donor power, meaning that the enthalpy of formation of Cu–N bonds is approximately the same in the two reactions. Under conditions of equal copper concentrations and when the concentration of methylamine is twice the concentration of ethylenediamine, the concentration of the bidentate complex will be greater than the concentration of the complex with 2 monodentate ligands. The effect increases with the number of chelate rings so the concentration of the EDTA complex, which has five chelate rings, is much higher than a corresponding complex with two monodentate nitrogen donor ligands and four monodentate carboxylate ligands. Thus, the phenomenon of the chelate effect is a firmly established empirical fact: under comparable conditions, the concentration of a chelate complex will be higher than the concentration of an analogous complex with monodentate ligands. The thermodynamic approach to explaining the chelate effect considers the equilibrium constant for the reaction: the larger the equilibrium constant, the higher the concentration of the complex.
Cell-penetrating peptide facilitated translocation is a topic of great debate. Evidence has been presented that translocation could use several different pathways for uptake. In addition, the mechanism of translocation can be dependent on whether the peptide is free or attached to cargo. The quantitative uptake of free or CPP connected to cargo can differ greatly but studies have not proven whether this change is a result of translocation efficiency or the difference in translocation pathway. It is probable that the results indicate that several CPP mechanisms are in competition and that several pathways contribute to CPP internalization.
== Clinical significance == Clinically important research of gel based in vitro 3D model for the osteocytic potentiality of human CD34+ stem cells has been described. The results confirm that the human CD34+ stem cells possess unique osteogenic differentiation potential and can be used in the early regeneration of injured bone. Osteocytes die as a consequence of senescence, degeneration/necrosis, apoptosis (programmed cell death), and/or osteoclastic engulfment. The percentage of dead osteocytes in bone increases with age from less than 1% at birth to 75% after age 80. Osteocyte apoptosis is thought to be related to decreased mechanotransduction, which possibly leads to the development of osteoporosis. Apoptotic osteocytes release apoptotic bodies expressing RANKL to recruit osteoclasts. Mechanical loading increases osteocyte viability in vitro, and contributes to solute transport through the lacuno-canalicular system in bone, which enhances oxygen and nutrient exchange and diffusion to osteocytes. Skeletal unloading has been shown to induce osteocyte hypoxia in vivo, this is when osteocytes undergo apoptosis and recruit osteoclasts to resorb bone. Microdamage in bone occurs as the result of repetitive events of cycling loading, and appears to be associated with osteocyte death by apoptosis, which appear to secrete a signal to target osteoclasts to perform remodeling at a damaged site.
Sources: en.wikipedia.org
In the field of atomic, molecular, and optical physics, a branching fraction refers to the probability of decay to a specific lower-lying energy states from some excited state. Suppose we drive a transition in an atomic system to an excited state |e⟩, which can decay into either the ground state |g⟩ or a long-lived state |d⟩. If the probability to decay (the branching fraction) into the |g⟩ state is
The report found that AI has significant negative impacts on land, water, and climate, as it uses large amounts of electricity, requires mining of minerals, and generates large amounts of electronic waste. In 2025, data centres consumed more electricity than Saudi Arabia, and ChatGPT alone consumed an amount of water equivalent to the needs of 500,000 people in Sub-Saharan Africa. The negative impacts are not distributed equally across the planet but are concentrated in some places. Data centres are often built in places already suffering from water deficit. For example, AI deployment has already led to an increase in water scarcity in Mexico and Uruguay. It created problems with energy supply in Ireland, which forbade construction of new data centres near Dublin until 2028. Measures can involve tradeoffs, for example, transitioning from coal to bioenergy reduces carbon footprint but increases the impact on land and water. Energy efficiency might not reduce environmental impact, because as AI becomes more efficient, it also becomes cheaper and more widely used.
==== Invasion preparedness ==== The Greenlandic government has asked citizens to prepare for a possible attack on Greenland by the United States, including by stockpiling supplies. According to a report by Danish broadcaster DR, published in March 2026, Danish forces also prepared defensive measures in early 2026, including the deployment of special forces units and the pre-positioning of medical supplies such as blood for potential casualties. Troops reportedly brought explosives intended to disable key airstrips in Nuuk and Kangerlussuaq to prevent American landings.
== Pharmacokinetics == With the once-monthly formulation of paliperidone palmitate, the time to peak is 13 days and the elimination half-life is 25 to 49 days; for the 3-month formulation, the time to peak is 30 to 33 days and the half-life is 84 to 95 days (deltoid muscle) or 118 to 139 days (gluteal). These data come from a 2021 review whose authors included employees of Janssen Research & Development, the manufacturer of paliperidone palmitate. The peak-to-trough ratio of paliperidone palmitate at steady state ranges from 1.56 to 1.70 with the 1- and 3-month formulations. No pharmacokinetic data for the 6-month formulation has been released as of January 2021. However, a 2025 case report described a patient who still had measurable plasma paliperidone concentrations in the low therapeutic range 886 days (2.5 years) after her last injection, indicating that in some individuals the drug may be released from the depot far longer than the predicted half‑life. The pharmacokinetic profile was originally derived from a 2009 pooled analysis of 18,530 paliperidone concentration samples from 1,795 subjects across six Phase I trials and five Phase II and III trials funded by Johnson & Johnson Pharmaceutical Research and Development, LLC. Invega Sustenna, Invega Trinza, and Invega Hafyera all utilize nanoparticle technology. The NanoCrystal® technology used in all three long-acting paliperidone products is manufactured by Alkermes plc.
Sources: en.wikipedia.org
The above descriptions ignore the effects of Gβγ–signalling, which can also be important, in particular in the case of activated Gαi/o-coupled GPCRs. The primary effectors of Gβγ are various ion channels, such as G-protein-regulated inwardly rectifying K+ channels (GIRKs), P/Q- and N-type voltage-gated Ca2+ channels, as well as some isoforms of AC and PLC, along with some phosphoinositide-3-kinase (PI3K) isoforms.
Bacteria in the genus Pseudomonas are able to aerobically grow on L-carnitine, as it is the bacteria's sole source of nitrogen and carbon. The L-carnitine is metabolized at its beta-hydroxy group by L-carnitine-3-dehydrogenase and the coenzyme NAD+, which forms 3-dehydrocarnitine; the 3-dehydrocarnitine then acts as an inducer for the enzyme, further allowing the enzyme to catalyze the reaction. The formed 3-dehydrocarnitine may also be broken down to form glycine betaine which is then metabolized through step demethylation to form glycine. Carnitine Carnitine dehydrogenase Enzyme Metabolism Pseudomonas
=== Legal status === In the Netherlands, midazolam is a List II drug of the Opium Law. Midazolam is a Schedule IV drug under the Convention on Psychotropic Substances. In the United Kingdom, midazolam is a Schedule 3/Class C controlled drug. In the United States, midazolam (DEA number 2884) is on the Schedule IV list of the Controlled Substances Act as a non-narcotic agent with low potential for abuse.
== Manufacturing == Commercial preparations of lente insulin are standardized to 30% semilente (amorphous precipitates of insulin), and 70% ultralente (crystallized insulin). In early versions, the semilente insulin was extracted from pigs, and the ultralente insulin was extracted from cows.
==== Teleostei ==== Order Anabantiformes Betta splendens, Siamese fighting fish (2018) Helostoma temminkii, Kissing gourami (2020) Order Anguilliformes Anguilla anguilla, European Eel (2012) Anguilla japonica, Japanese Eel (2022) Order Atheriniformes Atherinopsis californiensis, Jack silverside (2023) Order Beloniformes Oryzias latipes, medaka (2007) Order Callionymiformes Callionymus lyra, common dragonet (2020) Order Carangiformes Caranx ignobilis, Giant trevally (2022) Caranx melampygus, Bluefin trevally (2021) Pseudocaranx georgianus, New Zealand trevally (2021) Order Centrarchiformes Oplegnathus fasciatus, barred knifejaw (2019) Siniperca roulei (Slender Mandarinfish) (2025) Order Characiformes Astyanax jordani, Mexican cavefish (2014) Astyanax mexicanus, Mexican tetra (2021) Colossoma macropomum, Tambaqui (2021) Hasemania nana, Silvertip tetra (2013) Hyphessobrycon heterorhabdus, Flag tetra (2023) Petitella bleheri, Firehead tetra (2015) Psalidodon paranae, (2016) Order Cichliformes Oreochromis niloticus, Nile tilapia (2019) Maylandia zebra, Lake Malawi cichlid (2019) Order Clupeiformes Clupea harengus, Atlantic herring (2020) Coilia nasus, Japanese grenadier anchovy (2020) Sardina pilchardus, European pilchard (2019) Order Cypriniformes Anabarilius grahami, Kanglang fish (2018) Danio rerio, zebrafish (2007) Leuciscus baicalensis, Siberian dace (2014) Megalobrama amblycephala, Wuchang bream (2017) Metzia formosae, (2015) Opsarius caudiocellatus, (2022) Oxygymnocypris stewartii, (2019) Pseudobrama simoni (2020) Rhodeus ocellatus, Rosy bitterling (2020) Triplophysa bleekeri, Tibetan stone loach (2020) Order Cyprinodontiformes Fundulus catenatus, Northern studfish (2020) Fundulus olivaceus, Blackspotted topminnow (2020) Fundulus nottii, Bayou topminnow (2020) Fundulus xenicus, Diamond killifish (2020) Gambusia affinis, western mosquitofish (2020) Heterandria formosa, least killifish (2019) Micropoecilia picta, swamp guppy (2021) Xiphophorus maculatus, platyfish (2013) Nothobranchius furzeri, turquoise killifish (2015) Order Esociformes Esox lucius, northern pike (2014) Order Gadiformes Gadus macrocephalus, Pacific cod (2022) Gadus morhua, Atlantic cod (2011) Order Gasterosteiformes Gasterosteus aculeatus, three-spined stickleback (2006, 2012) Order Gobiiformes Oxyeleotris marmorata, marble goby (2020) Periophthalmus modestus, shuttles hoppfish or shuttles mudskipper (2022) Order Gymnotiformes Electrophorus electricus, electric eel (2014) Order Lampriformes Lampris incognitus, Smalleye Pacific Opah (2021) Order Osmeriformes Neosalanx tangkahkeii, Chinese icefish (2015) Protosalanx hyalocranius, clearhead icefish (2017) Order Osteoglossiformes Heterotis niloticus, African arowana (2020) Paramormyrops kingsleyae, mormyrid electric fish (2017) Scleropages formosus, Asian arowana (2016) Order Perciformes Centropyge bicolor, bicolor angelfish (2021) Chaetodon trifasciatus, melon butterflyfish (2020) Channa argus, northern snakehead (2017) Channa maculata, blotched snakehead (2021) Chelmon rostratus, copperband butterflyfish (2020) Chrysiptera cyanea, Sapphite damselfish (2024) Dissostichus mawsoni, Antarctic toothfish (2019) Eleginops maclovinus, Patagonian robalo (2019) Epinephelus moara, kelp grouper (2021) Larimichthys crocea, large yellow croaker (2014) Lutjanus campechanus, Northern red snapper (2020) Naso vlamingii, bignose unicornfish (2020) Parachaenichthys charcoti, Antarctic dragonfish (2017) Rachycentron canadum, Cobia (2024) Seriola dumerili, Greater amberjack (2017) Sillago sinica, chinese sillago (2018) Siniperca knerii, Big-Eye Mandarin Fish (2020) Sparus aurata, gilt-head bream (2018) Holacanthus passer, King Angelfish (2024) Oplegnathus fasciatus, Barred knifejaw (2024) Order Pleuronectiformes Microstomus kitt, Lemon sole (2025) Order Salmoniformes Salmo salar, Atlantic salmon (2016) Oncorhynchus mykiss, rainbow trout (2014) Oncorhynchus tshawytscha, Chinook salmon (2018) Salvelinus namaycush, Lake Trout (2021) Order Scorpaeniformes Sebastes schlegelii, Black rockfish (2018) Order Siluriformes Clarias batrachus, walking catfish (2018) Ictalurus punctatus, channel catfish (2016) Pangasianodon hypophthalmus, Iridescent shark catfish (2021) Silurus glanis, Wels catfish (2020) Order Spariformes Datnioides pulcher, Siamese tigerfish (2020) Datnioides undecimradiatus, Mekong tiger perch (2020) Order Syngnathiformes Syngnathus scovelli, Gulf pipefish (2016, 2023) Entelurus aequoreus, Snake pipefish (2024) Order Tetraodontiformes Diodon holocanthus, Long-spine porcupinefish (2020) Mola mola, ocean sunfish (2016) Takifugu rubripes, a puffer fish (2002) Tetraodon nigroviridis, a puffer fish (2004)
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.
Earlier approaches were largely hormonal or psychological in focus, whereas this compound acts on central melanocortin signalling. It is not a vasodilator and does not share the mechanism of phosphodiesterase inhibitors. Head-to-head comparative data are limited.
Placebo responses in desire trials are large, so the average drug-placebo separation is small. Reporting therefore relies on validated questionnaires with statistical ranges. Individual responses vary widely.
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.